Seriousness and expectedness together decide how fast a case moves:
- US, marketed products (21 CFR 314.80): a case that is serious and unexpected, foreign or domestic, is a 15-day Alert report. Everything else goes in the periodic report.
- EU (GVP Module VI): every serious valid case goes to EudraVigilance within 15 days, expected or not; non-serious valid cases within 90 days.
- Clinical trials: a serious, unexpected adverse reaction with a reasonable possibility that the drug caused it (often called a SUSAR) is expedited. ICH E2A and 21 CFR 312.32: 7 calendar days when it is fatal or life-threatening, 15 calendar days otherwise. In a trial, an event the investigator and the sponsor judge not related is not a suspected adverse reaction and is not expedited.
E2D adds that how serious expected reactions are expedited varies by country, and that non-serious reactions are not normally expedited anywhere.